First Patients Vaccinated in Clinical Trial of Experimental HIV Vaccine

Dr. David Diemert, director of The GW Vaccine Research Unit, was interviewed on CTV Your Morning about our current clinical trial of an experimental HIV vaccine.

“The future implications are huge if we could have an effective HIV vaccine that would prevent people from getting the infection and thereby not having to go on antiretroviral medication for the rest of their lives,” he says.

Latest News

A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below: